Innovative regenerative medicines in the EU: a better future in evidence?

BACKGROUND: Despite a steady stream of headlines suggesting they will transform the future of healthcare, high-tech regenerative medicines have, to date, been quite inaccessible to patients, with only eight having been granted an EU marketing licence in the last 7 years. Here, we outline some of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Corbett, Mark S., Webster, Andrew, Hawkins, Robert, Woolacott, Nerys
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Debate
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341436/
https://www.ncbi.nlm.nih.gov/pubmed/28270209
http://dx.doi.org/10.1186/s12916-017-0818-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341436/
https://www.ncbi.nlm.nih.gov/pubmed/28270209
http://dx.doi.org/10.1186/s12916-017-0818-4

Ejemplares similares